A second preclinical murine study presented by Dr. Louise Lines of Dartmouth demonstrated that treatment with an anti-VISTA antibody exerted multiple effects on tumor-associated macrophages (TAMs), including diminished myeloid suppression of T-cell proliferation, increased major histocompatibility complex expression on TAMs, and reduced expression of genes promoting T-cell quiescence. The gene discussed is VSIR; the disease is neoplasm.